EUVIMEDObjevte EUVIMED
Multizentrische StudieOpen access · CC BY 4.0

Complement Inhibition Therapy in Myasthenic Crisis—A Multicentre Retrospective Analysis of 17 Cases From Germany

Lea Gerischer iD, Maike Stein iD, Alice Schneider iD, Hanna Tangen, Johanna Loris, Stefanie Glaubitz iD, Jana Zschüntzsch iD, Ulrich Hofstadt-van Oy iD, Charlotte Schubert iD, Christoph Heesen iD, Melina Schlag, Tim Hagenacker iD and 13 more

European Journal of Neurology · 2026-04 · 33 (4)

DOI: 10.1111/ene.70596 ↗

At a glance

Multizentrische Studie in European Journal of Neurology, published online on 2026-04-15. Written by Lea Gerischer and 24 co-authors. Institution: Department of Neurology With Experimental Neurology, Charité - Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt-…. Major MEDLINE topics: Myasthenia Gravis, Antibodies, Monoclonal, Humanized, Complement Inactivating Agents. Cited 2 times so far (Crossref); 46 references. The full text is freely available (open access, CC BY 4.0).

AbstraktSubjectsBibliografické údajeCiteRelated studies

Abstract (original language)

Introduction

Generalized myasthenia gravis (gMG) may progress to life‐threatening myasthenic crises (MC) requiring mechanical ventilation. Standard therapy includes intravenous immunoglobulins (IVIg), plasmapheresis (PLEX), immunoadsorption (IA), and high‐dose corticosteroids. This study aimed to evaluate the real‐world effectiveness of complement‐inhibitors (C5‐I) in patients refractory to the standard treatment of MC (termed therapy‐refractory MC).

Methods

This multicentre, retrospective study included patients with acetylcholine‐receptor‐antibody positive (AChR‐ab+) gMG experiencing MC or severe exacerbations (MGFA IVb/V) treated with eculizumab or ravulizumab in the intensive or intermediate care unit (ICU/IMC). The primary outcome was the proportion of patients discharged from ICU/IMC within six weeks after C5‐I initiation (German Clinical Trials Registry; DRKS00032104).

Results

Among 17 identified cases, seven had thymoma‐associated MG (TAMG) and 10 had late‐onset MG; median age was 77 years. Five patients required non‐invasive and 12 invasive ventilation; nine underwent tracheotomy. Therapies included IVIg, PLEX, IA, and corticosteroids. Rituximab was added in two cases. Twelve patients received eculizumab and five ravulizumab. Median hospitalization before C5‐I initiation was 32 days (IQR 22–50) and median ICU‐stay was 17 days (IQR 4.5–35) thereafter. Fourteen patients (82%) reached the primary outcome. Two patients died due to bacterial sepsis; no meningococcal infection was observed.

Conclusion

In MC or severe exacerbations insufficiently responsive to standard treatment with IVIg and PLEX/IA, add‐on C5‐I therapy may represent an effective therapeutic approach. Importantly, TAMG, a subtype typically excluded from interventional trials yet often requiring more intensive therapy, also demonstrated clinical improvement. These findings warrant further systematic evaluation of C5‐I as adjunctive therapy for AChR‐ab+ therapy‐refractory MC.

Subjects

MeSH terms (MEDLINE)

Myasthenia GravisAntibodies, Monoclonal, HumanizedComplement Inactivating AgentsHumansFemaleRetrospective StudiesMaleAgedGermanyMiddle AgedAged, 80 and overTreatment Outcome

Author keywords

C5‐inhibitioneculizumabmyasthenic crisisneurocritical careravulizumab

Substances

Antibodies, Monoclonal, HumanizedeculizumabComplement Inactivating Agents

Authors and institutions

  • Department of Neurology With Experimental Neurology, Charité - Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany.
  • Neuroscience Clinical Research Center, Charité - Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany.
  • Berlin Institute of Health at Charité - Universitätsmedizin Berlin, Digital Health Center, Berlin, Germany.
  • Institute of Biometry and Clinical Epidemiology, Charité - Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany.
  • Department of Neurology, University Medical Center Göttingen, Göttingen, Germany.
  • Department of Neurology, Knappschaft Kliniken Dortmund, Dortmund, Germany.

ORCID profiles: Lea Gerischer, Maike Stein, Alice Schneider, Stefanie Glaubitz, Jana Zschüntzsch, Ulrich Hofstadt-van Oy, Charlotte Schubert, Christoph Heesen, Tim Hagenacker, Tobias Ruck, Paolo Doksani, Carla Dusemund, Meret Herdick, Julia Herzig-Nichtweiß, Philipp Mergenthaler, Frauke Stascheit, Lisa Schwarz, Sarah Hoffmann, Andreas Meisel, Sophie Lehnerer

Cite

APA

Gerischer, L., Stein, M., Schneider, A., Tangen, H., Loris, J., Glaubitz, S., Zschüntzsch, J., Oy, U. H., Schubert, C., Heesen, C., Schlag, M., Hagenacker, T., Oeztuerk, M., Ruck, T., Doksani, P., Dusemund, C., Herdick, M., Herzig-Nichtweiß, J., Mergenthaler, P., …, & Lehnerer, S. (2026). Complement Inhibition Therapy in Myasthenic Crisis—A Multicentre Retrospective Analysis of 17 Cases From Germany. European Journal of Neurology, 33(4). https://doi.org/10.1111/ene.70596

Vancouver

Gerischer L, Stein M, Schneider A, Tangen H, Loris J, Glaubitz S, et al. Complement Inhibition Therapy in Myasthenic Crisis—A Multicentre Retrospective Analysis of 17 Cases From Germany. European Journal of Neurology. 2026;33(4). doi:10.1111/ene.70596

BibTeX
@article{Gerischer2026,
  author = {Gerischer, Lea and Stein, Maike and Schneider, Alice and Tangen, Hanna and Loris, Johanna and Glaubitz, Stefanie and Zschüntzsch, Jana and Oy, Ulrich Hofstadt-van and Schubert, Charlotte and Heesen, Christoph and Schlag, Melina and Hagenacker, Tim and Oeztuerk, Menekse and Ruck, Tobias and Doksani, Paolo and Dusemund, Carla and Herdick, Meret and Herzig-Nichtweiß, Julia and Mergenthaler, Philipp and Stascheit, Frauke and Suboh, Amani and Schwarz, Lisa and Hoffmann, Sarah and Meisel, Andreas and Lehnerer, Sophie},
  title = {Complement Inhibition Therapy in Myasthenic Crisis—A Multicentre Retrospective Analysis of 17 Cases From Germany},
  journal = {European Journal of Neurology},
  year = {2026},
  volume = {33},
  number = {4},
  doi = {10.1111/ene.70596}
}
Start for free →